Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Tanja Trarbach,Anke Reinacher-Schick,Susanne Hegewisch-Becker,U. Vanhoefer,Thomas Frieling,Lasse Lehnert,Wolff Schmiegel,Ullrich Graeven

Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

2010

Tanja Trarbach
Anke Reinacher-Schick
Susanne Hegewisch-Becker
U. Vanhoefer
Thomas Frieling
Lasse Lehnert
Wolff Schmiegel
Ullrich Graeven

Background: This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in p

Keywords:

Capecitabine
Gefitinib
Second-line therapy
Colorectal cancer
Oncology
Internal medicine
Medicine
advanced colorectal cancer
phase i study
phase i ii
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations